Given the premise that TSP-1 serves as a regulator of neuronal activity-driven glioma growth, we sought to target TSP-1 therapeutically using gabapentin (GBP), which blocks the thrombospondin receptor α2δ-1 (ref. 47). The gene discussed is THBS1; the disease is glioma.